Angiotensin 1-7 as a Therapy in the Treatment of COVID-19
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Phase 2 ,double blind, randomized study of therapy with Angiotensin 1-7 in COVID-19 patients.
120 confirmed SARS-CoV-2 infected patients who exhibit moderate- clinical symptoms including
dyspnea, cough and fever, hospitalized in the KETER department in several hospitals in
Israel, will be enrolled. 60 patients will receive Ang 1-7 subcutaneously 500 mcg/kg /day. 60
patients will receive placebo : NaCl 0.9% 2 ml -control arm .
Treatment duration: 14 days or until clinical improvement that enables discharge from
hospital.
(the shortest time will be the limiting factor in treatment duration). Follow-up-30 days.
14-30 days after discharge from hospital: we will contact the patient via phone to ask
questions related to any possible adverse reaction to the drug and general health.